论文部分内容阅读
Pharmacia公司已向法国、意大利和英国等许多欧洲国家以及澳大利亚和新西兰递交了多巴胺D。受体激动剂卡麦角林上市用于治疗帕金森病的申请。卡麦角林已在许多欧洲国家上市，用于治疗高催乳激素血症和某些需要抑制泌乳的疾病。Pharmacia公司认为此药的独特之处是有较长的半衰期
Pharmacia has submitted dopamine D to many European countries such as France, Italy and the United Kingdom, as well as to Australia and New Zealand. The receptor agonist cabergoline is marketed for the treatment of Parkinson’s disease. Cabergoline has been marketed in many European countries for the treatment of hyperprolactinemia and certain diseases that require suppression of lactation. Pharmacia believes this medicine is unique in that it has a longer half-life